PARTNER WITH US

Position Yourself as a Leader in the Heart Failure Drug Development Space

The unmet need for heart failure drug development is growing. Biopharma continues to grapple with heterogeneity, disease understanding and back translation from clinical trials. In the context of these challenges, drug developers are actively seeking solution providers with sophisticated biomarkers that assist with HF stratification, robust models which capture the complexity of the disease and insights-driven technology to assist with the backtranslation from clinical trials.

Download the event guide to learn more about how you can showcase your brand and capitalize on our audience of leading companies with active pipelines in HF, HFpEF, HFrEF, HFmrEF.

What Experts Need from You

Sophisticated imaging to act as a biomarker and accurately stratify patients.

CROs which can accelerate and support preclinical development for HF and cardiomyopathies.

Preclinical models – showcase your expertise in developing translatable in vivo and in vitro models that reliably predict how drug interact with cardiac muscle.

Insights driven technology to allow backtranslation from clinical trials.

Why Partner?

Bespoke Networking Opportunities

Form connections with top cardio decision-makers and key opinion leaders, opening doors to potential collaborative partnerships and business prospects.

Brand Exposure

Position your brand prominently and showcase cutting-edge solutions to an exclusive audience actively seeking new solutions to optimize heart failure drug development.

Cutting Edge Research

Keep your finger on the pulse and stay ahead of the curve about how the heart failure field is moving.

Deliver a presentation

Put your solutions and expertise in front of the preclinical decision makers working to identify promising compounds and drive success in the lab.

Our Partners

Perspectum_RGB_NoTM (1)
antaros
logo-Cardiomedex
syncrosome